Updates on COVID-19 (including visitor restrictions and mask requirements), monkeypox and flu. See Communicable Disease Updates

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.


Clinical Trial at Scripps Paves Way for More Patients to Benefit from Minimally Invasive Heart Valve Procedure

Cardiologist discusses transcatheter aortic valve replacement

Paul Teirstein, MD, cardiologist, specializes in interventional cardiology.

Dr. Paul Teirstein, Interventional Cardiology, Scripps Clinic

Cardiologist discusses transcatheter aortic valve replacement

A recent San Diego Union-Tribune article highlighted Scripps Health’s participation in an important clinical trial that paves the way for more people to benefit from a minimally invasive heart valve replacement procedure as an alternative to open-heart surgery.

Paul Teirstein, MD, an interventional cardiologist at Scripps Clinic, discussed the catheter-based procedure, known as transcatheter aortic valve replacement or TAVR, and its expected expansion to healthier, lower-risk patients who, under current guidelines, must undergo heart surgery to get a new valve.

Read the story in The San Diego Union-Tribune: Octogenerarian weightlifter embraces alternative to open heart surgery.

Media Contact

Keith Darce